Connect Biopharma Holdings (CNTB) Earnings Analysis

Connect Biopharma Holdings (CNTB) next reports earnings on 2026-08-12, consensus EPS -0.32 USD. Last quarter (2026-03-31) it beat with EPS -0.27 USD vs -0.3 USD est (+10%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -4.40.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CNTB next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.32 USD
Revenue estimate0.00B

CNTB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-31-0.27 USD-0.3 USD+10%Beat
2025-08-13-0.23 USD-0.22 USD-4.5%Miss
2025-03-31-0.05762 USD-0.27 USD+78.7%Beat
2024-09-050.01895 USD-0.02808 USD+167.5%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

CNTB valuation and analyst view

Trailing P/E-4.40
Trailing EPS-0.5032 USD
Price / book2.92
Dividend yield0.00%
Market cap0.14B
Analyst consensusBuy (5 buy / 0 hold / 0 sell)
Avg price target6.4 USD

Related research pages

Frequently asked questions

When is Connect Biopharma Holdings (CNTB)'s next earnings date?

Connect Biopharma Holdings is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.32 USD and revenue estimate of 0.00B.

Did CNTB beat earnings last quarter?

In its 2026-03-31 report, CNTB posted EPS of -0.27 USD versus a -0.3 USD estimate — a beat of 10%.

What is CNTB's earnings track record?

Over the last 4 reported quarters with consensus data, CNTB beat estimates 3 times (75%).

What is CNTB's current P/E ratio and EPS?

CNTB trades at a trailing P/E of -4.40 on trailing EPS of -0.503197987782968 USD.

What do analysts rate CNTB?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 6.4 USD.